Allen Mangel, a gastroenterologist with extensive experience in clinical
research, has joined RTI Health Solutions (RTI-HS) as Global Head of
"Our business is growing in the areas of drug safety research,
patient registries, and nontraditional clinical trials," said Elizabeth
Andrews, Vice President, RTI Health Solutions. "As we develop creative
designs for these studies and put them in the field, Allen's leadership,
clinical knowledge, and experience in clinical research practice are
critical to our success.
"Having a physician as an integral part of our team adds substantially
to the quality and credibility of our work, helping to round out the
multidisciplinary team that is already strong in other areas."
A long-time resident of the Triangle, Dr. Mangel comes to RTI-HS from
Salix Pharmaceuticals, where he served at vice president of research
and development. Prior to that he was executive director and site head
of Regulatory and Technical Services at Quintiles, Inc., and he served
in several roles at GlaxoWellcome/GSK in the area of gastroenterology
clinical development and research. Dr. Mangel also served as assistant
professor of medicine at Duke University's Medical Center.
This experience will be a significant benefit to RTI-HS. Andrews explained, "Allen's
broad network of colleagues in clinical research is already bringing
us new opportunities, such as a new partnership with the Duke Clinical
Research Institute on a very interesting project for a pharmaceutical
company. He is well respected by senior-level decision makers at the
Food and Drug Administration, academic collaborators, and industry scientists."
Dr. Mangel earned his M.D. from the Georgetown University School of
Medicine and his B.S., M.S., and Ph.D. in Physiology from the University
of Illinois. He has published numerous articles in scientific periodicals
such as Nature, the American Journal of Physiology, Science, the American
Journal of Cardiology, The Lancet, and the American Journal